Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
2025 · 2nd Quarter (Apr 1 - June 30)
ASTELLAS PHARMA US, INC.
Filed by ASTELLAS PHARMA US, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- Not reported
- Expenses
- $670,000.00
- Registrant
- ASTELLAS PHARMA US, INC.
- Client
- ASTELLAS PHARMA US, INC.
- Filing UUID
- 3e73e7fb-53c0-4f98-b25f-1c5f713fc335
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to OBBA (Pub. L. No: 119-21).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.